Agios Pharmaceuticals
Surveying great inventors and businesses
Axial: https://linktr.ee/axialxyz
Axial partners with great founders and inventors. We invest in early-stage life sciences companies such as Appia Bio, Seranova Bio, Delix Therapeutics, Simcha Therapeutics, among others often when they are no more than an idea. We are fanatical about helping the rare inventor who is compelled to build their own enduring business. If you or someone you know has a great idea or company in life sciences, Axial would be excited to get to know you and possibly invest in your vision and company . We are excited to be in business with you - email us at info@axialvc.com
Agios Pharmaceuticals recently made its pivot from cancer to rare disease complete. The company is legendary with 2 drug approvals treating over 6K patients. Now Agios is focusing on Mitapivat, recently approved to treat hemolytic anemia: https://lnkd.in/dpTNKT9m
In 2020, Agios sold off their cancer pipeline to Servier for $1.8B in cash. Despite pioneering drug development in cancer metabolism, Agios faced commercial hiccups, and focused on Mitapivat/PKR to streamline their pipeline and likely make them a more attractive acquisition target.
The company was founded in 2008 to commercialize research centered around cancer metabolism. Agios' platform was based on work from Lewis Cantley at Harvard Medical School, Craig Thompson who was at UPenn at the time, and Tak Mak from the University of Toronto. From their leading research in cancer metabolism, mainly discoveries from Cantley's Lab who discovered metabolic enzymes that drove several cancers, Agios has been able to drive 2 drug approvals along with a legendary partnership with Celgene and build a business set up to continue successful development of new medicines for patients.
Agios’ open job positions
https://lnkd.in/dXCbx6KY